Nūhou ʻOihana
Nā Hopena Hou o ka CD7-Targeted CAR-T Therapy no T-ALL a me T-LBL
Ua hōʻike ʻia kahi noiʻi hou i nā hopena hoʻohiki o ka CD7-targeted chimeric antigen receptor (CAR) T cell therapy i ka mālama ʻana i nā maʻi me ka relapsed a refractory T-cell acute lymphoblastic leukemia (T-ALL) a me T-cell lymphoblastic lymphoma (T-LBL).
Ka Uhi ʻana o ka Hālāwai Makahiki a me ka Hōʻikeʻike ASH 2024
E mālama ʻia ana ka Hālāwai Makahiki 66 o ka ʻAhahui ʻAmelika o Hematology (ASH) mai ka lā 7-10 o Dekemaba, 2024, ma ke Kikowaena ʻAha Kūkākūkā o San Diego, e hōʻike ana i ka noiʻi hou a me nā holomua i ka hematology.
Manaʻolana Hou i ka Lapaʻau ʻana i ka Maʻi Kanesa: Puka Mai ka Lapaʻau TILs ma ke ʻano he Palena Aʻe
ʻOiai nā pilikia e hoʻomau nei i ka ʻoihana a me ke kālepa ʻana, ke hoʻoponopono ʻia nei nā palena o ka lāʻau CAR-T e kahi ala hou e hoʻohiki nei: ka lāʻau Tumor-Infiltrating Lymphocyte (TIL). Ke hōʻike nei kēia holomua i kahi au hou i ke kaua ʻana i nā puʻupuʻu paʻa.
ʻO nā Cellular Therapies ka wā e hiki mai ana o ka maʻi Autoimmune?
Hiki paha i kahi lāʻau lapaʻau kipi no nā maʻi ʻaʻai ke mālama a hoʻonohonoho hou i ka ʻōnaehana pale e hāʻawi i ke kala ʻana no ka manawa lōʻihi a i ʻole e hoʻōla paha i kekahi mau maʻi autoimmune.
